Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Texas Instruments Incorporated (TXN) Price & Performance

Adaptive Biotechnologies CorpTrade
Texas Instruments IncorporatedTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Texas Instruments Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while Texas Instruments Incorporated trades at $284.1 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 63.2× Adaptive Biotechnologies Corp's market cap, and Texas Instruments Incorporated pays a 2.03% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTTXN
Market Cap
$4.05B$256.11B
Sector
HealthTechnology
52-Week High
$25.45$332.35
52-Week Low
$12.30$153.33
Enterprise Value
$4.12B$263.16B
Dividend Yield
2.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Texas Instruments Incorporated

Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.

Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Texas Instruments Incorporated

Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.

Read more on TXN